OOIR: Observatory of International Research

Papers

(The H4-Index of Multiple Sclerosis and Related Disorders is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Test-retest reliability of the Swedish version of the Modified Fatigue Impact Scale in people with mild to moderate multiple sclerosis	72
Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with mul	58
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis	58
Characteristics of Patients with Newly Diagnosed Multiple Sclerosis: A Five-Year Study at Benghazi Medical Center, Benghazi, Libya	57
Real-World Evidence with Five-Year Data (2017-2022) on the Use of Cladribine Tablets in Patients with Multiple Sclerosis in England: an Updated Analysis from the CLARENCE Study	47
EDSS and Infratentorial White Matter Lesion Volume are Considered Predictors of Fatigue Severity in RRMS	46
The Management of Lower Urinary Tract Symptoms in Multiple Sclerosis: an Umbrella Review	45
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis	45
Influence of Cigarette, and Waterpipe Smoking, Alcohol, and Drug Consumption on the Occurrence of Late-Onset Multiple Sclerosis	45
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study	44
57. Cognitive Decline and Motor Handicap in Multiple Sclerosis Patients	40
Cognitive outcomes in late-onset versus adult-onset Multiple Sclerosis	40
143. Navigating the Maze of Multiple Sclerosis Disease Modifying Therapies: Insights from Iran's National MS Registry	39
Coexistence of epilepsy or seizure and multiple sclerosis; a single center experience	39
Impact of insurance status on MRI phenotypes in MS	38
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis	38
157. Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Subjects	37
125. Investigating Psychoses in Pediatric-Onset Multiple Sclerosis: A Systematic Review of Case Reports	36
Macular vascular density alteration patterns in paediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography	35
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?	35
Lipid measures are associated with cognitive functioning in multiple sclerosis patients	35
Symptoms of PTSD and depression in newly diagnosed people with multiple sclerosis during the outbreak Oct.7th war on Gaza: A case-control study from Jordan	35
Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?	34
Feasibility and usability evaluation of a gamified fatigue management mobile application for persons with multiple sclerosis in everyday life	34
Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis	34

Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort	34
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination	34
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy–A case series	34
The relationship between cognitive impairment, cognitive fatigue, and visual evoked potential latency in people with multiple sclerosis	33
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina	33
Sarcopenia in patients with multiple sclerosis	33
Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression	32
Characterizing causal relationships of visceral fat and body shape on multiple sclerosis risk	32
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies	32
Sexual problems in MS: Sex differences and their impact on quality of life	32